These strongly suggest that the PD1/PD-L1 axis is an important therapeutic target under conditions of neutrophil infiltration, and targeting TANs may be an important strategy to prevent PD1/PD-L1-associated tumor immune evasion. This evidence concerns the gene CD274 and neoplasm.